alexa Progestin Intrauterine Devices And Metformin: Endometrial Hyperplasia And Early Stage Endometrial Cancer Medical Management | 71166
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Congress on Contemporary Issues in Women Cancers & Gynecologic Oncology

Oroma Nwanodi
A.T. Still University, USA
ScientificTracks Abstracts: Gynecol Obstet (Sunnyvale)
DOI: 10.4172/2161-0932-C1-018
Abstract
Globally, endometrial cancer is the sixth leading cause of female cancer-related deaths. Endometrial hyperplasia (EH), has a lifetime progression rate to endometrial cancer ranging from 5%, if simple without atypia, to 40%, if complex with atypia. Site specific, long-acting intrauterine devices (IUDs) provide fertility sparing, progestin-based EH management. Progesterone sensitizing metformin potentially offers outcome improvements. PubMed searches provided sufficient literature for a review of medical management of EH and early stage EC since 2012. The high-dose frameless IUD has achieved sustained regression of Grade 3 endometrial intraepithelial neoplasia for 14 years. Case series on early stage EC treatment with IUDs have 75% or greater regression rates. For simple through complex EH with atypia, the 52 mg-IUD has achieved 100% complete regression in 6-months. Metformin 1000 mg daily with Cyproterone/Ethinyl Estradiol 2 mg/35 mcg 21 days per month for 6 months achieved 100% complete regression of Stage 1A Grade 1 EC. Metformin, 500 mg twice daily has achieved 95.5% regression of simple EH through early stage EC at 3-months. IUDs show an outcome advantage over oral progestins. Outcomes from the feMMe trial for the 52 mg-IUD and metformin will fill a gap in the literature. Studies on metformin for EH, and studies of progestins or metformin for early stage EC management have been underpowered and possibly used too low dosages to achieve significant differences in, or optimal outcomes for the treatment modalities.
Biography

Oroma Nwanodi, MD, DHSc graduated from Meharry Medical College of Nashville, Tennessee in the United States of America as a Medical Doctor in May, 2001. She completed Doctor of Health Sciences at A T Still University, Mesa, Arizona, in December, 2016. She has practiced in California, Missouri, and Wyoming. Currently, she provides locum tenens services in Minnesota. She has over 20 publications. She has presented on Acupuncture and a range of Obstetrics and Gynecology subjects. Her publications and presentations may be accessed via academia.edu and researchgate.net.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7